Palisade Bio Announces Inducement Grants Under Nasdaq

0
78


Carlsbad, CA, Sept. 23, 2022 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI), a scientific stage biopharmaceutical firm advancing therapies for acute and power gastrointestinal (GI) problems, immediately introduced that it had made fairness grants to 2 new staff underneath its 2021 Inducement Plan.

On August 29, 2022, the Company’s Compensation Committee granted choices to 2 new non-executive staff overlaying an combination of 93,000 shares of the Company’s frequent inventory as materials inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

The choices have an train worth equal to the closing worth of the Company’s frequent inventory on the date of grant. The choices granted to every worker vest in equal proportions every quarter for 3 years. In all circumstances, the choices are contingent on every worker’s continued service with the Company on the relevant vesting date.

About Palisade Bio 

Palisade Bio is a late-stage biopharmaceutical firm targeted on growing therapeutics that shield the integrity of the intestinal barrier. The Company makes use of over three a long time of analysis and established science that hyperlinks the position of intestinal barrier biology and human illness to develop novel therapeutics that focus on and enhance the integrity of the intestinal barrier.

The Company’s lead program, LB1148, is a broad-spectrum serine protease inhibitor which acts to neutralize digestive enzymes, doubtlessly decreasing intestinal injury. In a number of scientific research, LB1148 has demonstrated constructive ends in accelerating the time to return of postoperative bowel operate, and the Company not too long ago offered evaluation that LB1148 lowered the incidence and severity of post-surgical stomach adhesions. LB1148 is at the moment being evaluated in a Phase 3 scientific research for accelerating the return of postoperative bowel operate and in a Phase 2 research for the prevention of post-surgical stomach adhesions.

See also  New Analysis of SOLOIST-WHF Trial Underscores

The Company believes that addressing the disruption of the intestinal barrier has the potential to basically change the best way ailments are handled and to determine new requirements of affected person care. For extra data, please go to www.palisadebio.com.

Forward Looking Statements
This communication accommodates “forward-looking” statements for functions of the secure harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements embrace statements concerning Palisade’s intentions, beliefs, projections, outlook, analyses or present expectations regarding, amongst different issues: the potential to basically change the best way ailments are handled, the completion of enrollment for the Phase 3 research, the potential for the statistically important Phase 3 knowledge to permit for NDA approval, and the potential for LB1148 to determine the usual of care, if permitted. Any statements contained on this communication that aren’t statements of historic truth could also be deemed to be forward-looking statements. These forward-looking statements are based mostly upon Palisade’s present expectations. Forward-looking statements contain dangers and uncertainties. Palisade’s precise outcomes and the timing of occasions might differ materially from these anticipated in such forward-looking statements because of these dangers and uncertainties, which embrace, with out limitation, the corporate’s skill to advance its scientific packages, the unsure and time-consuming regulatory approval course of; the corporate’s skill to realize extra financing to fund scientific growth and the corporate’s skill to adjust to the continued itemizing necessities for Nasdaq. Additional dangers and uncertainties will be present in Palisade Bio’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022. Palisade expressly disclaims any obligation or endeavor to launch publicly any updates or revisions to any forward-looking statements contained herein to mirror any change in Palisade’s expectations with regard thereto or any change in occasions, situations or circumstances on which any such statements are based mostly.

Investor Relations Contact
JTC Team, LLC
Jenene Thomas
833-475-8247
PALI@jtcir.com

See also  Fortis Hospital, Bannerghatta Road introduces De-addiction Programme

Source: Palisade Bio



Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here